Deltec Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Deltec Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-11,000	Closed	-$647K	–	219
2020 Q2	$647K	Buy	+11,000	New	+$658K	0.14%	128
2016 Q4	–	Sell	-52,972	Closed	-$2.86M	–	164
2016 Q3	$2.86M	Buy	+52,972	New	+$3.4M	0.65%	48

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Deltec Asset Management's BMY Position: Q3 2020 in Review

Deltec Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2020, closing a stake of 11,000 shares — an estimated $647K sold.

Deltec Asset Management first reported a position in BMY in Q3 2016 and held it in 2 quarters. The position peaked at $2.86M in Q3 2016. 2,215 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

Deltec Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2020 after selling out during the quarter.
Deltec Asset Management sold 11,000 Bristol-Myers Squibb shares in Q3 2020, an estimated $647K.
Deltec Asset Management first reported a position in Bristol-Myers Squibb in Q3 2016 and held it in 2 quarters.
Deltec Asset Management's Bristol-Myers Squibb position peaked at $2.86M in Q3 2016.
2,215 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on Deltec Asset Management's 13F filing for Q3 2020, filed 23 Oct 2020.